gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PTGXHealthcarePharmaceuticals

Protagonist Therapeutics, Inc (PTGX)

$143.37+2.23%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$143.37▲ 87.41% in range
Nov 4, 2025Low $76.50 · High $158.62Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Protagonist Therapeutics closed at $143.37 on Nov 4, up 2.23%, 9.6% below its 52-week closing high. Volume of 777.8K shares was 1.12× its 20-day average (close to normal).

Split-adjusted performance: +3.4% over one month, +37.9% over six months, +88.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $213.47M, up 3749.2% from a year earlier, with a net margin of 76.3%.

Short interest was 10.3M shares at the Oct 15 settlement, up 10.2% from the prior report (16.8% of float, 12.0 days to cover).

Market cap$9.28B64.7M shares
Revenue · quarter$213.5M+3749.2% YoY
Diluted EPS$2.29—
P/E · TTM111.9×P/S 32.9×
Net margin76.3%Gross 100.0%
Dividend yieldNone
52-week range75.95 – 158.62−9.6% from high
Volume777.8K1.12× 20-day avg
Volatility · 60d32.0%Annualised
Short % of float16.8%12.0 days to cover
Net cash$782.6MCash $782.6M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.9%1M +3.4%3M −1.9%6M +37.9%YTD +64.2%1Y +88.8%3Y +904.0%5Y +350.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum90
Revenue growth98
Net margin97
Value (low P/E)10
Size95

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short10.3M+10.2% vs prior
Days to cover12.0Settled Oct 15
% of float16.8%
Short vol. 10d63.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PTGXProtagonist Therapeutics$143.37+2.23%+37.9%+3749.2%76.3%111.9$9.28B
SYRESpyre Therapeutics$99.04−0.23%+35.7%———$9.26BCompare
MDGLMadrigal Pharmaceuticals$400.43+1.04%−25.8%+50.1%12.9%—$9.25BCompare
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43BCompare
CYTKCytokinetics$63.60+2.07%−15.0%−57.1%−694.4%—$8.84BCompare
ARWRArrowhead Research$61.65+3.56%−22.1%+171.0%−258.2%—$8.71BCompare
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare
BMRNBioMarin Pharmaceuticals$57.13+2.64%+4.6%+19.9%4.5%151.5$11.06BCompare

News about Protagonist Therapeutics

All news →
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research · Oct 15, 2026▲ PositiveJohnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVieBenzinga · Mar 19, 2026▲ PositiveProtagonist Stock Up 120%, but One Fund Just Revealed a $170 Million ExitThe Motley Fool · Feb 25, 2026Neutral

Quick answers

What does Protagonist Therapeutics do?
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases.
What is PTGX's market cap?
$9.28B, based on the Nov 4 close of $143.37.
What is PTGX's P/E ratio?
111.9× trailing-twelve-month earnings of $82.91M.
Does Protagonist Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PTGX is sold short?
10.3M shares, 16.8% of float, as of Oct 15, 2026.
What sector is PTGX in?
Healthcare, in the Pharmaceuticals industry.

About Protagonist Therapeutics

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

HQ: Newark, CA141 employeesListed Aug 11, 2016protagonist-inc.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology